Many people are adequately protected from COVID19 with the multiple effective vaccines. However, immunocompromised patients with cancer on active therapy may not develop immunity to COVID19. For those patients, long acting antibody (Evusheld) is now available to protect against COVID19. Evusheld may reduce the risk of infection by 77% especially in people with other complicating medical conditions. Queens Medical Associates, in partnership with Northwell Health’s Cancer Institute, is offering this antibody therapy to patients. Please speak to us about Evusheld. There is ample supply. Patients will be able to get the injection after a quick review and referral to the nearby distribution site.